Ignite Creation Date:
2024-05-06 @ 8:08 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06269120
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-21
First Post:
2024-02-13
Brief Title:
SEMA-CardioDiab HUNGARY A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels Weight and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
SEMA-CardioDiab HUNGARY A Multicentre Prospective Non-interventional Study to Evaluate Glycemic Control and Weight Changes in Patients With Type 2 Diabetes Initiating Treatment With Oral Semaglutide by Cardiologists or Diabetologists as Part of Local Clinical Practice in Hungary
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Participant will get oral semaglutde as prescribed by the study doctor The study will last for about 26 4 weeks 5 to 7 months Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctors appointment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1290-8109 | OTHER | World Health Organization WHO | None |